Treatment of systemic-onset juvenile arthritis with canakinumab

Joachim Peitz, Gerd Horneff Pediatric Rheumatology Centre, Department of General Pediatrics and Neonatology, Asklepios Clinic, Sankt Augustin, Germany Abstract: Treatment of systemic-onset juvenile idiopathic arthritis is challenging, but the availability of cytokine antagonists targeting interleu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Peitz J, Horneff G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/974a3e6cbe3c4fa79506ad41d2b57406
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:974a3e6cbe3c4fa79506ad41d2b57406
record_format	dspace
spelling	oai:doaj.org-article:974a3e6cbe3c4fa79506ad41d2b574062021-12-02T02:46:03ZTreatment of systemic-onset juvenile arthritis with canakinumab1179-156Xhttps://doaj.org/article/974a3e6cbe3c4fa79506ad41d2b574062015-02-01T00:00:00Zhttp://www.dovepress.com/treatment-of-systemic-onset-juvenile-arthritis-with-canakinumab-peer-reviewed-article-OARRRhttps://doaj.org/toc/1179-156X Joachim Peitz, Gerd Horneff Pediatric Rheumatology Centre, Department of General Pediatrics and Neonatology, Asklepios Clinic, Sankt Augustin, Germany Abstract: Treatment of systemic-onset juvenile idiopathic arthritis is challenging, but the availability of cytokine antagonists targeting interleukin-1 and interleukin-6 have markedly advanced the therapeutic options. In this review, we focus on the current experience with canakinumab, an interleukin-1 monoclonal human antibody for the treatment of systemic-onset juvenile idiopathic arthritis and describe its efficacy and safety. Canakinumab is an important, safe, and valid drug in the treatment of systemic-onset juvenile idiopathic arthritis. Keywords: anakinra, canakinumab, interleukin-1, interleukin-6, systemic-onset juvenile idiopathic arthritisPeitz JHorneff GDove Medical PressarticleDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol 2015, Iss default, Pp 23-31 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the musculoskeletal system RC925-935
spellingShingle	Diseases of the musculoskeletal system RC925-935 Peitz J Horneff G Treatment of systemic-onset juvenile arthritis with canakinumab
description	Joachim Peitz, Gerd Horneff Pediatric Rheumatology Centre, Department of General Pediatrics and Neonatology, Asklepios Clinic, Sankt Augustin, Germany Abstract: Treatment of systemic-onset juvenile idiopathic arthritis is challenging, but the availability of cytokine antagonists targeting interleukin-1 and interleukin-6 have markedly advanced the therapeutic options. In this review, we focus on the current experience with canakinumab, an interleukin-1 monoclonal human antibody for the treatment of systemic-onset juvenile idiopathic arthritis and describe its efficacy and safety. Canakinumab is an important, safe, and valid drug in the treatment of systemic-onset juvenile idiopathic arthritis. Keywords: anakinra, canakinumab, interleukin-1, interleukin-6, systemic-onset juvenile idiopathic arthritis
format	article
author	Peitz J Horneff G
author_facet	Peitz J Horneff G
author_sort	Peitz J
title	Treatment of systemic-onset juvenile arthritis with canakinumab
title_short	Treatment of systemic-onset juvenile arthritis with canakinumab
title_full	Treatment of systemic-onset juvenile arthritis with canakinumab
title_fullStr	Treatment of systemic-onset juvenile arthritis with canakinumab
title_full_unstemmed	Treatment of systemic-onset juvenile arthritis with canakinumab
title_sort	treatment of systemic-onset juvenile arthritis with canakinumab
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/974a3e6cbe3c4fa79506ad41d2b57406
work_keys_str_mv	AT peitzj treatmentofsystemiconsetjuvenilearthritiswithcanakinumab AT horneffg treatmentofsystemiconsetjuvenilearthritiswithcanakinumab
_version_	1718402179265462272

Treatment of systemic-onset juvenile arthritis with canakinumab

Ejemplares similares